Study Shows Immunotherapy Alters Bone Marrow in Leukemia Patients
A recent study published in Science Advances reveals that immunotherapy treatment may change the bone marrow environment in patients with acute myeloid leukemia (AML). Researchers found that some patients showed signs of immune system response after treatment with pembrolizumab and decitabine. The study used advanced techniques to analyze how immune cells interact with leukemia cells in the bone marrow.
Scientists studying acute myeloid leukemia (AML) found that immunotherapy may alter the bone marrow environment where cancer cells live, potentially enhancing the immune system's response. The study, published in Science Advances, analyzed bone marrow samples from AML patients who had relapsed or did not respond to previous treatments.
Patients were treated with pembrolizumab and decitabine. While not effective for all, some patients showed signs of immune cell activation in the bone marrow. Researchers used advanced tools to examine individual cells in the bone marrow, revealing changes in cell neighborhoods and communication after treatment.
Gege Gui, the study's first author, highlighted how this research sheds light on the interaction between the immune system and cancer cells. Christopher Hourigan, a senior author, emphasized the importance of detailed analysis in understanding treatment outcomes for AML patients.
The study involved collaboration among researchers with expertise in genomics, computational analysis, tumor immunology, and tissue imaging.
According to the source: Mirage News.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
